Return to homepagePandemic Pact

COVID rates and risk factors in systemic autoimmune rheumatic diseases [Funder: Singer Family Fund for SLE research]

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    Other Funders (Canada)

  • Principal Investigator

    Sasha Bernatsky

  • Research Location

    Canada

  • Lead Research Institution

    Research Institute of McGill University Health Centre

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Prognostic factors for disease severity

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Systemic autoimmune rheumatic diseases are complex chronic conditions characterized by an overactive immune system, and requires long-term therapies with immunomodulating agents. A key example of one such disease is systemic lupus (SLE) which is characterized by B and T cell abnormalities and the production of autoantibodies that results in organ damage. The majority of SLE patients are treated with hydroxychloroquine but in addition many receive more profound immunosuppressant therapy. They also are often treated with NSAIDs, ACE inhibitors, and ARBs. Our study will assess the incidence of COVID19 infection and ensuing complications (hospitalization, ARDS, death) as well as factors potentially associated with these outcomes (hydroxychloroquine, non-steroidal anti-inflammatories, immunosuppressants, ACEI inhibitors, ARBs).